Xalatan

Reduction of elevated IOP in patients w/ open-angle glaucoma, chronic angle closure glaucoma, & ocular HTN; paed patients w/ elevated IOP & paed glaucoma.

Adult (including the elderly) & paed patient 1 drop in affected eye(s) once daily, optimally in the evening. Max: Once daily. Administer at least 5 min apart if used w/ >1 topical ophth drug.

Hypersensitivity.

Avoid in patients w/ active herpes simplex keratitis & w/ history of recurrent herpetic keratitis specifically associated w/ prostaglandin analogues. May gradually increase brown pigment of iris; change eyelashes & vellus hair in treated eye including increased length, thickness, pigmentation, number of lashes & hairs, & misdirected growth of eyelashes; eyelid skin darkening. Potential for heterochromia in patients receiving unilateral treatment. Macular edema including cystoid macular edema in aphakic & pseudophakic patients w/ torn posterior lens cap, or those w/ known risk factors for macular edema. Inflammatory neovascular glaucoma. Patients w/ history of herpetic keratitis. Regularly examine patients who develop increased iris pigmentation. Remove contact lenses before instillation & reinsert after 15 min. Not to drive or use machines until transient vision blurring is resolved. Pregnancy & lactation. Childn <1 yr. Pre-term infants (<36 wk gestational age).

Eye irritation (burning, grittiness, itching, stinging & foreign body sensation), eye pain, eyelash & eyelid vellus hair changes (increased length, thickness, pigmentation & number of eyelashes), ocular hyperaemia, iris hyperpigmentation, blepharitis, conjunctivitis. Paed: Nasopharyngitis & pyrexia.

Paradoxical elevations in IOP w/ use of ≥2 prostaglandins, prostaglandin analogs or derivatives.

Antiglaucoma Preparations

S01EE01 - latanoprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma.

E-D